48,xyyy disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: 48X005 MIFTS: 39	48,xyyy Categories: Fetal diseases, Neuronal diseases, Rare diseases, Reproductive diseases
Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for 48,xyyy

MalaCards integrated aliases for 48,xyyy:

Name: 48,xyyy ⁵²

48,xyyy Syndrome ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Fetal diseases
Anatomical: Neuronal diseases Reproductive diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Congenital malformations, deformations and chromosomal abnormalities

Chromosomal abnormalities, not elsewhere classified

Other sex chromosome abnormalities, male phenotype, not elsewhere classified

Other specified sex chromosome abnormalities, male phenotype

Orphanet: ⁵⁸

Rare neurological diseases

Rare infertility disorders

Developmental anomalies during embryogenesis

External Ids:

ICD10 via Orphanet ³³ Q98.8

Orphanet ⁵⁸ ORPHA99329

Sources

Summaries for 48,xyyy

NIH Rare Diseases : ⁵² The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 99329 Definition A rare Y chromosome number anomaly that affects only males and is characterized by mild-moderate developmental delay (especially speech), normal to mild intellectual disability , large, irregular teeth with poor enamel, tall stature and acne. Radioulnar synostosis and clinodactyly have also been associated. Boys generally present normal genitalia, while hypogonadism and infertility is frequently reported in adult males. Visit the Orphanet disease page for more resources.

MalaCards based summary : 48,xyyy, also known as 48,xyyy syndrome, is related to radioulnar synostosis and hypogonadotropic hypogonadism. The drugs Progesterone and Ezetimibe have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and lung, and related phenotypes are hypertelorism and short neck

Sources

Related Diseases for 48,xyyy

Diseases related to 48,xyyy via text searches within MalaCards or GeneCards Suite gene sharing:

#	Related Disease	Score	Top Affiliating Genes
1	radioulnar synostosis	10.2
2	hypogonadotropic hypogonadism	10.2

Sources

Symptoms & Phenotypes for 48,xyyy

Human phenotypes related to 48,xyyy:

⁵⁸ ³¹ (show all 31)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	hypertelorism ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0000316
2	short neck ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0000470
3	high palate ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0000218
4	global developmental delay ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0001263
5	depressed nasal bridge ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0005280
6	delayed speech and language development ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0000750
7	pes planus ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0001763
8	feeding difficulties ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0011968
9	intellectual disability, mild ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0001256
10	long philtrum ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0000343
11	thick lower lip vermilion ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0000179
12	recurrent upper respiratory tract infections ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0002788
13	epicanthus ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0000286
14	acne ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0001061
15	abnormal dermatoglyphics ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0007477
16	male hypogonadism ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0000026
17	aggressive behavior ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0000718
18	asthma ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0002099
19	azoospermia ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0000027
20	impulsivity ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0100710
21	radioulnar synostosis ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0002974
22	tall stature ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0000098
23	abnormal renal morphology ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0012210
24	primary gonadal insufficiency ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0008193
25	dislocated radial head ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0003083
26	hypoplasia of dental enamel ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0006297
27	low frustration tolerance ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0000744
28	irregularly spaced teeth ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0006316
29	intellectual disability ⁵⁸		Very frequent (99-80%)
30	behavioral abnormality ⁵⁸		Very frequent (99-80%)
31	abnormality of the foot ⁵⁸		Very frequent (99-80%)

Sources

Drugs & Therapeutics for 48,xyyy

Drugs for 48,xyyy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1659)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Progesterone

Approved, Vet_approved

Phase 4

57-83-0

5994

Ezetimibe

Approved

Phase 4

163222-33-1

150311

Amantadine

Approved

Phase 4

768-94-5

2130

Cefuroxime

Approved

Phase 4

55268-75-2

5361202 5479529

Digoxin

Approved

Phase 4

20830-75-5

30322 2724385

Acarbose

Approved, Investigational

Phase 4

56180-94-0

441184

Nepafenac

Approved, Investigational

Phase 4

78281-72-8

151075

Fluvoxamine

Approved, Investigational

Phase 4

54739-18-3

3404 5324346

Riociguat

Approved

Phase 4

625115-55-1

Diltiazem

Approved, Investigational

Phase 4

42399-41-7

39186

Lincomycin

Approved, Vet_approved

Phase 4

154-21-2

656509

Fenoldopam

Approved

Phase 4

67227-56-9, 67227-57-0

3341

Eleuthero

Approved, Experimental

Phase 4

Hexetidine

Approved, Investigational

Phase 4

141-94-6

Bosentan

Approved, Investigational

Phase 4

147536-97-8

104865

Eszopiclone

Approved, Investigational

Phase 4

138729-47-2

969472

Trimetazidine

Approved, Investigational

Phase 4

5011-34-7

Adalimumab

Approved

Phase 4

331731-18-1

16219006

Abacavir

Approved, Investigational

Phase 4

136470-78-5

65140 441300

Emtricitabine

Approved, Investigational

Phase 4

143491-57-0

60877

Donepezil

Approved

Phase 4

120014-06-4

3152

Celecoxib

Approved, Investigational

Phase 4

169590-42-5

2662

Zidovudine

Approved

Phase 4

30516-87-1

35370

Nifedipine

Approved

Phase 4

21829-25-4

4485

Saw palmetto

Approved, Experimental, Investigational

Phase 4

Flurbiprofen

Approved, Investigational

Phase 4

5104-49-4

3394

Neomycin

Approved, Vet_approved

Phase 4

1404-04-2

8378

Eplerenone

Approved

Phase 4

107724-20-9

150310 443872

Dalteparin

Approved

Phase 4

9005-49-6

Sufentanil

Approved, Investigational

Phase 4

56030-54-7

41693

Octreotide

Approved, Investigational

Phase 4

83150-76-9

383414 6400441

Omalizumab

Approved, Investigational

Phase 4

242138-07-4

Norepinephrine

Approved

Phase 4

51-41-2

439260

Terlipressin

Approved, Investigational

Phase 4

14636-12-5

72081

Pamidronate

Approved

Phase 4

40391-99-9

4674

Saquinavir

Approved, Investigational

Phase 4

127779-20-8

60787

Interferon beta-1a

Approved, Investigational

Phase 4

145258-61-3

6438354

Natalizumab

Approved, Investigational

Phase 4

189261-10-7

Indinavir

Approved

Phase 4

150378-17-9

5362440

Orphenadrine

Approved

Phase 4

83-98-7

4601

Dezocine

Approved, Investigational

Phase 4

53648-55-8

40841 3033053

Neostigmine

Approved, Vet_approved

Phase 4

59-99-4

4456

Methocarbamol

Approved, Vet_approved

Phase 4

532-03-6

4107

Fosamprenavir

Approved

Phase 4

226700-79-4

131536

Desogestrel

Approved

Phase 4

54024-22-5

40973

Etonogestrel

Approved, Investigational

Phase 4

54048-10-1

40976 6917715

Atorvastatin

Approved

Phase 4

134523-00-5

60823

chloroquine

Approved, Investigational, Vet_approved

Phase 4

54-05-7

2719

Tavaborole

Approved, Investigational

Phase 4

174671-46-6

Nefopam

Approved, Investigational

Phase 4

13669-70-0

Interventional clinical trials:

(show top 50) (show all 10000)

#	Name	Status	NCT ID	Phase	Drugs
1	A Prospective, Randomized, Multicenter, Open-label Study Evaluating HBeAg Seroconversion in HBeAg Positive CHB Patients on Treatment With NA Switched to Combined Therapy With Peginterferon Alfa-2a and NA for 48 Weeks	Unknown status	NCT02474316	Phase 4	Peginterferon alfa-2a;nucleos(t)ide analgoue
2	Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive. Randomized Clinical, Not Masked, Trial Comparing DRVr3TC, ABC3TC (Kivexa) RPV, or EVG COBI FTC TDF (Stribild) for 48 Weeks	Unknown status	NCT02470650	Phase 4	elvitegravir/cobicistat/emtricitabine/tenofovir;Darunavir;abacavir/lamivudine;Ritonavir;Lamivudine;rilpivirine
3	Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients	Unknown status	NCT02327702	Phase 4	Emtricitabine
4	Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis—a Multicentre, Prospective, Double-blind, Double-dummy, Randomized Controlled Clinical Trial	Unknown status	NCT02063100	Phase 4	Shenyankangfu tablets;Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 100mg;Losartan potassium 100mg
5	A Multi-center, Open Label, Randomized Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Capsule Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients	Unknown status	NCT01436539	Phase 4	Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
6	Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy	Unknown status	NCT01893788	Phase 4	Aliskiren;Eplerenone
7	A Phase IV Multicenter Study of the Efficacy and Safety of 48-Week Induction Treatment With TRIZIVIR (Abacavir 300 Mg/Lamivudine 150 Mg/Zidovudine 300 Mg Combination Tablet BID) With Efavirenz (600 Mg QD) Followed by 48-Week Randomized, Open-Label, Maintenance Treatment With TRIZIVIR With or Without Efavirenz in HIV-1 Infected Antiretroviral Therapy Naive Subjects	Unknown status	NCT00011895	Phase 4	Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
8	The Efficacy and Safety of the Anti Hepatitis B Placenta Transfer Factor Injection in the Treatment of HBeAg Positive Chronic Hepatitis B, Randomized, Double Blind, Placebo Controlled, Multi Center Clinical Trial	Unknown status	NCT02412319	Phase 4	Anti-HBV placenta transfer factor injection
9	The Effect of Ketamine on Production of Inflammatory Markers in Post Operative Patients in Mulago Hospital: A Randomized Clinical Trial	Unknown status	NCT01339065	Phase 4	Ketamine
10	Multi-center, Randomized, Open Label, Comparative, Phase IV Study to Evaluate the Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid for 48 Weeks in Advanced IgA Nephropathy	Unknown status	NCT02981212	Phase 4	Mycophenolate Mofetil;ACE inhibitor;Corticosteroid;ARB
11	A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of "Response-Guided-Therapy (RGT)" Strategy on Optimal Nucleoside Analogue (NUC)-Experienced Patients	Unknown status	NCT02560649	Phase 4	Peginterferon alfa-2a plus Entecavir;Peginterferon alfa-2a plus Lamivudine;Peginterferon alfa-2a plus Adefovir;Peginterferon alfa-2a plus Tenofovir;Entecavir;Lamivudine;Adefovir;Tenofovir disoproxil
12	Efficacies of Entecavir Add on Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 6 Months Treatment of Peginterferon Alpha 2a	Unknown status	NCT02368288	Phase 4	entecavir
13	Efficacies of Entecavir Add on HBeAg Negative Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 3 Months of Peginterferon Alpha 2a Treatment	Unknown status	NCT02365402	Phase 4	Entecavir
14	Open, Randomized and Multicenter Phase IV Study to Compare the Efficacy and Safety of Two Different Treatments Duration 24 Versus 48 Weeks in Chronic Hepatitis C Genotypes 2 and/or 3 co-Infected HIV-HCV Patients.	Unknown status	NCT00611819	Phase 4	Peg interferon + Ribavirin;Peg interferon + Ribavirin
15	Prospective, Double-blinded, Randomised, Placebo Controlled Trial of Pre-emptive Analgesia to Prevent Pain Following Sternotomy for Cardiac Surgery.	Unknown status	NCT01480765	Phase 4	Pregabalin;Ketamine infusion;Placebo capsules;Placebo infusion
16	Sedation of Mechanically Ventilated Critically Ill Patients: Midazolam Versus Dexmedetomidine	Unknown status	NCT01256866	Phase 4	Dexmedetomidine;Midazolam
17	Prospective Analysis of the Incidence of Ventilator-associated Pneumonia Related to the Humidification System: Heat and Moisture Exchanger Versus Heated Humidification	Unknown status	NCT01546974	Phase 4
18	Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches: A Study on Practicability With Patients Maintained With Daily Dosages Between 60mg and 100mg Methadone.	Unknown status	NCT00750217	Phase 4	Buprenorphine patch and sublingual tablets
19	Efficacy and Safety of an Initial Regimen Raltegravir (RAL) + Lamivudine/Abacavir Fixed-Dose Combination (3TC/ABC FDC) for 48 Weeks in ART-naïve, HIV/TB Co-Infected Adult Subjects Receiving Rifabutin-containing, 1-line Anti-TB Therapy	Unknown status	NCT01059422	Phase 4	Raltegravir; Abacavir/Lamivudine
20	A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily	Unknown status	NCT00214435	Phase 4	once daily minimum 3-drug regimen of anti-retroviral medications
21	A Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis	Unknown status	NCT00761098	Phase 4	Standard Care;Experimental
22	A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One ®) ) Versus Triple Therapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide) Versus the Standard of Care Regimen(Reiferon Retard® + Ribavirin) in the Treatment of Naïve Chronic Hepatitis- C Among the Egyptian Population. Effectiveness Will be Evaluated Based on Sustained Viral Response (SVR)	Unknown status	NCT01896609	Phase 4	Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
23	A Multicenter, Open-label, Prospective Study to Evaluate Antiviral Efficacy and Safety of Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection	Unknown status	NCT01594905	Phase 4	Entecavir + Tenofovir (MDR group)
24	Post Operative Pain Control Among Intrathecal 0.1 mg Morphine, Femoral Nerve Block, or Periarticular Infiltration of 20 mL of 0.25% Bupivacaine in Patients Post Intramedullary Hip Screw	Unknown status	NCT01219088	Phase 4	Bupivacaine, morphine
25	A Randomized, Controlled, Open-label, Multicenter Clinical Trial to Evaluate the Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides	Unknown status	NCT02644538	Phase 4	PegIFN alfa-2a
26	Postoperative Analgesia After Thoracotomy Without Thoracic Epidural Analgesia: Continuous Wound Catheter Analgesia Associated With Intravenous Morphine Patient-Controlled-Analgesia (PCA)	Unknown status	NCT01698203	Phase 4	ropivacaine 0.75% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun);Placebo;ropivacaine 0.2% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)
27	An Open, Single-Arm, Multi-Center, Phase IV Pilot Study of Treatment of Antiretroviral Naive HIV-1 Infected Patients With Tenofovir Disoproxil Fumarate in Combination With Emtricitabine and Zidovudine	Unknown status	NCT00199121	Phase 4	Zidovudine (drug)
28	Chlorhexidine Gluconate for Prevention of Ventilator Associated Pneumonia in a Pediatric Intensive Care Unit.	Unknown status	NCT01883596	Phase 4	0.12% chlorhexidine solution;Placebo
29	Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients	Unknown status	NCT02370979	Phase 4
30	Programmatic Implementation of ACTs in Malawi: Safety and Effectiveness of Combination Therapies With Repeated Treatments for Uncomplicated P. Falciparum Malaria Over a Three-year Period	Unknown status	NCT01038063	Phase 4	Artemether-lumefantrine combination
31	A Phase IV, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement	Unknown status	NCT00354445	Phase 4	pegaptanib sodium (Macugen)
32	Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard®) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial	Unknown status	NCT01649245	Phase 4	Reiferon retard
33	A Clinical Trial of the Effect of Midazolam on the Cerebral Metabolism and Inflammatory Response in Patients With Moderate and Severe Traumatic Brain Injury	Unknown status	NCT02071407	Phase 4	Midazolam;Placebo
34	Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial	Unknown status	NCT02231125	Phase 4	Losartan;Abelmoschus manihot
35	Neutrophil gElatinase-associated Lipocalin alloWs Intensive treatMent Of cOntrast Induced Nephropathy in Patients With Urgent/Emergency Percutaneous Coronary Intervention	Unknown status	NCT01491243	Phase 4	Intensive treatment with sodium bicarbonate;Standard treatment with saline infusion
36	A Multi Center, Phase IIIb Study to Evaluate the Efficacy of Response Guided Therapy Using Quantitative HBsAg Measurement in Patient With HBeAg Positive Chronic Hepatitis B:	Unknown status	NCT01456312	Phase 4	Peginterferon alfa-2a;Entecavir
37	Impact of Pretreatment With Omega 3 Enriched Lipid Emulsion on Early Neurological Complications After Living Donor Liver Transplantation. A Randomized Controlled Trial>	Unknown status	NCT02544919	Phase 4	SMOF lipid (SMOFLIPID) pre treatment
38	Analysis of Proximal Renal Tubular Function of "Real World" Chronic Hepatitis B (CHB) Patients Who Are Suppressed on TDF and Switched to TAF	Unknown status	NCT02957994	Phase 4	Tenofovir alafenamide fumarate
39	Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease	Unknown status	NCT00941642	Phase 4	Lovaza;placebo control
40	Multicenter Prospective Trial to Investigate Accuracy of Ultrasound to Predict Relapse After Discontinuation of Infliximab and Efficacy/Safety of Readministration of Infliximab in Patients With Rheumatoid Arthritis in Low Disease Activity	Unknown status	NCT02770794	Phase 4	Infliximab
41	Naproxen for Acute Pain After Surgery: A Randomized, Placebo-Controlled Trial	Unknown status	NCT00615875	Phase 4	naproxen;placebo
42	Effect of Vitamin D Supplementation on Bone Turnover Markers During Tenofovir-Emtricitibine Pre-Exposure Prophylaxis in Men Who Have Sex With Men; A Sub-study of CCTG 595	Unknown status	NCT02367599	Phase 4	Vitamin D Supplement
43	Adductor Canal Block Versus Femoral Nerve Block for Analgesia After Anterior Cruciate Ligament Reconstruction Arthroscopically	Unknown status	NCT02355093	Phase 4	ropivacaine
44	Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant	Unknown status	NCT03359746	Phase 4	Grazoprevir/Elbasvir
45	Cardiovascular Safety Research: Bupivacaine With Vasoconstrictor Versus Ropivacaine in Brachial Plexus Block	Unknown status	NCT00523289	Phase 4	Bupivacaine;Ropivacaine
46	An Open Label, Randomized, Parallel Design Estimation Pilot Study to Compare the Effectiveness of 36 vs 48 Wks PegIntron Plus Ribavirin Treatment for HCV Patients Without Rapid Virologic Response(RVR) But With Undetectable HCV RNA at wk 8	Unknown status	NCT01683786	Phase 4	Pegintron + Riba
47	An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks	Unknown status	NCT00426296	Phase 4	atazanavir (Reyataz);ritonavir (Norvir)
48	Antibiotic Prophylaxis in Prosthetic Breast Reconstructions	Unknown status	NCT02012517	Phase 4	Prolonged antibiotic treatment;Short antibiotic course (standard of care)
49	Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study)	Unknown status	NCT00120419	Phase 4	mycophenol mofetil (MMF, Cellcept®) 500 mg BID
50	A Randomised Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis	Unknown status	NCT02238860	Phase 4	Entacavir;Tenofovir

Search NIH Clinical Center for 48,xyyy

Sources

Genetic Tests for 48,xyyy

Sources

Anatomical Context for 48,xyyy

MalaCards organs/tissues related to 48,xyyy:

⁴⁰

Testes, Liver, Lung, Brain, Kidney, Heart, Breast

Sources

Publications for 48,xyyy

Articles related to 48,xyyy:

(show top 50) (show all 30000)

#	Title	Authors	PMID	Year
1	Co-existence of OXA-48 and NDM-1 in colistin resistant Pseudomonas aeruginosa ST235. ⁶¹	Vatansever C...Can F	31964275	2020
2	Rapid Identification of OXA-48-like, KPC, NDM, and VIM Carbapenemase-Producing Enterobacteriaceae From Culture: Evaluation of the RESIST-4 O.K.N.V. Multiplex Lateral Flow Assay. ⁶¹	Song W...Jeong SH	31858767	2020
3	Isolation of virulent phages infecting dominant mesophilic aerobic bacteria in cucumber pickle fermentation. ⁶¹	Zheng XF...Jiao XA	31703878	2020
4	Disease detection at the 48-month exit round of the HPV FOCAL cervical cancer screening trial in women per-protocol eligible for routine screening. ⁶¹	Coldman AJ...Ogilvie GS	31245842	2020
5	Short-term safety and effectiveness of sugammadex for surgical patients with end-stage renal disease: a two-centre retrospective study. ⁶¹	Adams DR...Sakai T	31721151	2020
6	Cytotoxicity and inflammatory response of different types of provisional restorative materials. ⁶¹	Campaner M...Pesqueira AA	31918345	2020
7	Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials. ⁶¹	Cahn P...Smith KY	31834000	2020
8	Correction to: A pH-responsive genetic sensor for the dynamic regulation of D-xylonic acid accumulation in Escherichia coli. ⁶¹	Banares AB...Chung WJ	31950218	2020
9	Neurofibromas of the oral and maxillofacial complex: A 48-year retrospective study. ⁶¹	de Pontes Santos HB...de Almeida Freitas R	31675118	2020
10	The complex phenotype of spinocerebellar ataxia type 48 in eight unrelated Italian families. ⁶¹	Lieto M...Silvestri G	31571321	2020
11	Molecular characterization of carbapenem-resistant Klebsiella pneumoniae ST14 and ST512 causing bloodstream infections in ICU and surgery wards of a tertiary university hospital of Verona (northern Italy): co-production of KPC-3, OXA-48, and CTX-M-15 β-lactamases. ⁶¹	Piccirilli A...Cornaglia G	31924425	2020
12	Dynamic cytotoxicity of ZnO nanoparticles and bulk particles to Escherichia coli: A view from unfixed ZnO particle:Zn2+ ratio. ⁶¹	Song K...Yao L	31945654	2020
13	Cytogenotoxic effects of venlafaxine hydrochloride on cultured human peripheral blood lymphocytes. ⁶¹	Ayabakti S...Yavuz Kocaman A	30025480	2020
14	Role of 68Ga-Prostate-Specific Membrane Antigen PET/CT in Disease Assessment in Glioblastoma Within 48 Hours of Surgery. ⁶¹	Gupta M...Ahlawat P	31977462	2020
15	Resveratrol treatment during maturation enhances developmental competence of oocytes after prolonged ovary storage at 4 °C in the domestic cat model. ⁶¹	Piras AR...Bogliolo L	31951984	2020
16	The First 48 Consecutive Patients with 3-Year Symptom Score Follow-Up Post-Prostate Artery Embolization (PAE) at a Single-Centre University Hospital. ⁶¹	Maclean D...Hacking N	31797101	2020
17	Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir. ⁶¹	Wang YH...Tang H	31609007	2020
18	The influence of time-to-surgery on mortality after a hip fracture. ⁶¹	Kristiansson J...Nellgard B	31652349	2020
19	Biological properties of Phoma macrostoma related to non-dermatophyte onychomycosis. ⁶¹	Kukhar E...Kiyan V	31993320	2020
20	The combination therapy of Peginterferonα and entecavir for HBeAg-positive chronic hepatitis B with high HCC risk. ⁶¹	Xiong F...Lu J	31689542	2020
21	Corrigendum to "Immediate efficacy of Gufoni maneuver for horizontal canal benign paroxysmal positional vertigo (HC-BPPV): A meta-analysis" [Auris Nasus Larynx (2020) 48-54]. ⁶¹	Fu W...Wang X	31311683	2020
22	Individualized Preconditioning for ABO-Incompatible Living-Donor Kidney Transplantation: An Initial Report of 48 Cases from China. ⁶¹	Wang XD...Lin T	32029699	2020
23	Central mfERG amplitude ratio as a predictor for visual outcome of macular hole surgery. ⁶¹	Moreto R...Gekeler K	31482394	2020
24	Analgesic and antiallodynic activity of novel anticonvulsant agents derived from 3-benzhydryl-pyrrolidine-2,5-dione in mouse models of nociceptive and neuropathic pain. ⁶¹	Rapacz A...Filipek B	31874144	2020
25	A 48-year-old female with an exophytic nodule in the buccal mucosa. ⁶¹	Rumayor Pina A...Flores Flores D	30249538	2020
26	Transmission and evolution of OXA-48-producing Klebsiella pneumoniae ST11 in a single hospital in Taiwan. ⁶¹	Lu MC...Lai YC	31665400	2020
27	Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19). ⁶¹	Shefner J...Apple S	31621933	2020
28	Temporal Occurrence of Arrhythmic Complications After Alcohol Septal Ablation. ⁶¹	El-Sabawi B...Eleid MF	31973555	2020
29	Small Nucleolar RNA Host Gene 1 (SNHG1) and Chromosome 2 Open Reading Frame 48 (C2orf48) as Potential Prognostic Signatures for Liver Cancer by Constructing Regulatory Networks. ⁶¹	Zhang H...Chen Z	32036380	2020
30	Predicting chronic algal toxicity from 1- to 48-h pulsed exposures to mine site waters using time-averaged concentrations. ⁶¹	Angel BM...Simpson SL	32036098	2020
31	Effects of a polysaccharide-rich extract derived from Irish-sourced Laminaria digitata on the composition and metabolic activity of the human gut microbiota using an in vitro colonic model. ⁶¹	Strain CR...Allsopp PJ	30805695	2020
32	Variation in clinical usefulness of biomarkers of acute kidney injury in young children undergoing cardiac surgery. ⁶¹	Baek HS...Cho MH	32023398	2020
33	Effects of Hot Air Treatments on Postharvest Storage of Newhall Navel Orange. ⁶¹	Wan C...Chen C	32024051	2020
34	[Volume-based haemostasis reserves in blood product free liver transplantations]. ⁶¹	Rengeine Kiss T...Fazakas J	32037866	2020
35	Longitudinal analysis of ESBL and carbapenemase carriage among Enterobacterales and Pseudomonas aeruginosa isolates collected in Europe as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme, 2013-17. ⁶¹	Kazmierczak KM...Sahm DF	32040168	2020
36	Office-Based Weight Loss Counseling Is Ineffective in Liver Transplant Recipients. ⁶¹	Patel SS...Siddiqui MS	31440999	2020
37	Use of a Glass Membrane Pumping Emulsification Device Improves Systemic and Tumor Pharmacokinetics in Rabbit VX2 Liver Tumor in Transarterial Chemoembolization. ⁶¹	Masada T...Kichikawa K	31542274	2020
38	Outcome of short- to medium-term migration analysis of a cementless short stem total hip arthroplasty using EBRA-FCA: a radiological and clinical study. ⁶¹	Jahnke A...Ishaque BA	31786645	2020
39	Acute and chronic effects of competition on ankle dorsiflexion ROM in professional football players. ⁶¹	Moreno-Perez V...Romero-Rodriguez D	31072261	2020
40	Epidemiological and Accounting Analysis of Ground Ambulance Whole Blood Transfusion. ⁶¹	Mapp JG...Prehospital Research and Innovation in Military and Expeditionary Environments (PRIME) Group	31847923	2020
41	Mycoplasma genitalium Antimicrobial Resistance in Community and Sexual Health Clinic Patients, Auckland, New Zealand. ⁶¹	Vesty A...Basu I	31961302	2020
42	The effect of bisphosphosphonates on bone turnover and bone balance in postmenopausal women with osteoporosis: The T-score bone marker approach in the TRIO study. ⁶¹	Gossiel F...Eastell R	31740343	2020
43	Early Administration of Oseltamivir Within 48 Hours After Onset of Flulike Symptoms Can Reduce the Risk of Influenza B Virus-Associated Pneumonia in Hospitalized Pediatric Patients with Influenza B Virus Infection. ⁶¹	Dai Z...Fan K	31929434	2020
44	Prevalence of viral load suppression, predictors of virological failure and patterns of HIV drug resistance after 12 and 48 months on first-line antiretroviral therapy: a national cross-sectional survey in Uganda. ⁶¹	Ssemwanga D...Uganda HIV Drug Resistance Technical Working Group	32025714	2020
45	Correction: Highly efficient room-temperature phosphorescence achieved by gadolinium complexes. ⁶¹	Sun B...Huang C	31967159	2020
46	Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113. ⁶¹	Havens PL...Mulligan K	31179503	2020
47	Time to rethink endpoints for new clinical trials of antiretrovirals? Long-term re-suppression of HIV RNA with integrase inhibitors. ⁶¹	Pepperrell T...Hill A	31876594	2020
48	The Role of Sleep Duration and Sleep Problems During Childhood in the Development of ADHD in Adolescence: Findings From a Population-Based Birth Cohort. ⁶¹	Carpena MX...Tovo-Rodrigues L	31617436	2020
49	Developmental toxicity in embryo-larval zebrafish (Danio rerio) exposed to strobilurin fungicides (azoxystrobin and pyraclostrobin). ⁶¹	Kumar N...Crago J	31600620	2020
50	Cytotoxicity of Ear Drop Excipients in Human and Mouse Tympanic Membrane Fibroblasts. ⁶¹	Dirain CO...Antonelli PJ	31791190	2020

Sources

Genes for 48,xyyy

Sources

Variations for 48,xyyy

Sources

Expression for 48,xyyy

Search GEO for disease gene expression data for 48,xyyy.

Sources

Pathways for 48,xyyy

Sources

GO Terms for 48,xyyy

Sources

Sources for 48,xyyy

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia